

September 25, 2018
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses)
 Issued by way of Third Party Allotment**

TOKYO, Japan, September 25, 2018—Symbio Pharmaceuticals Limited announces the large volume exercise of the 45th stock acquisition rights, allotted to EVO FUND based on the board resolution announced on April 9, 2018, during the period from September 6, 2018 to September 25, 2018, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 45 th Stock Acquisition Rights
(2)	Number of issued shares from the last disclosure	2,000,000 shares
(3)	Number of stock acquisition rights being exercised from the last disclosure and the ratio to the entire issue	2,000,000 units (Ratio to the total number of stock acquisition rights issued 20,000,000 units : 10.00%)
(4)	Number of unexercised stock acquisition rights at the last disclosure	3,220,000 units
(5)	Number of remaining unexercised stock acquisition rights as of today	1,220,000 units

(6) Exercise status from the last disclosure

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
September 6 (Thu.) to September 12 (Wed.)	—	—	124	—
September 13 (Thu.) to September 20 (Thu.)	—	—	118	—
September 21 (Fri.)	—	—	113	—
September 25 (Tue.)	2,000,000	—	113	2,000,000

※Number of issued shares at the end of the previous month : 72,644,824 shares [of which 75 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.